CAMP4 Therapeutics Corporation
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Joshua Mandel-Brehm
- Full Time Employees
- 48
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- One Kendall Square Bldg 1400 West, 3rd Floor Cambridge MA United States of America 02139
- IPO Date
- Oct 11, 2024
- CIK
- 0001736730
- Website
- camp4tx.com
- Similar Companies
- Business
- CAMP4 Therapeutics Corporation (NASDAQ:CAMP), a clinical-stage biopharmaceutical company, discovers and develops regulatory RNA-based therapeutics designed to upregulate gene expression and restore healthy protein levels for patients with genetic diseases; its proprietary RAP Platform identifies regulatory RNAs associated with genetically validated targets in haploinsufficient and recessive disorders. The lead product candidate, CMP-CPS-001, an antisense oligonucleotide targeting CPS1, advances in a Phase 1 clinical trial for urea cycle disorders; CMP-SYNGAP addresses SYNGAP1-related neurodevelopmental disorders in preclinical development with a Phase 1/2 trial planned for the second half of 2026; the pipeline also includes preclinical RNA Actuator candidates such as CMP-SCN for SCN-related epilepsies, CMP1403 for gram-positive bacterial infections, OTC RNA Actuator for ornithine carbamoyltransferase deficiency, and programs for Diamond-Blackfan anemia, with an initial focus on metabolic and central nervous system diseases. Founded in 2015 and headquartered in Cambridge, Massachusetts, the company operates primarily in the United States and targets rare genetic conditions affecting the liver and central nervous system. In September 2025, CAMP4 completed an oversubscribed private placement raising up to $100 million, including $50 million in upfront proceeds led by Coastlands Capital with participation from Janus Henderson Investors, Balyasny Asset Management, Vivo Capital, 5AM Ventures, Adage Capital Management, Trails Edge Capital Partners, and the SynGAP Research Fund; proceeds fund the SYNGAP1 program's preclinical and clinical advancement. Recent leadership changes include Doug Williams assuming the role of Board Chair in September 2025 and Daniel Tardiff elevated to Chief Scientific Officer effective October 1, 2025; the company went public via IPO in October 2024 and reported second-quarter 2025 financial results with ongoing R&D investments.
Company News
CAMP4 to Participate in Upcoming Investor Conferences
Canadian GoldCamps Completes Acquisition of Initial 85% Interest in Stealthwall West Gold Project in Northeastern Québec
Canadian GoldCamps Enters into Agreement to Acquire Stealthwall West Gold Project in Northeastern Québec
CAMP4 Therapeutics Corporation (CAMP) Reports Q2 Loss, Tops Revenue Estimates
CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights
CAMP4 advances rare disease treatment for SYNGAP1 into human trials
SIX FLAGS GREAT AMERICA ANNOUNCES CAMP TIMBER TRAIL, AN ALL-NEW FAMILY ADVENTURE FOR 2027
CAMP4 Therapeutics Announces Second Closing of $100 Million Private Placement
Canadian GoldCamps Completes Independent NI 43-101 Technical Report for the Mercator Gold Project
CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
New Strong Sell Stocks for July 16th
CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Discovr Radio to Embed Across All Four Days of CAMP Toronto in First Major Activation with Beatcave
New Analysis Strengthens Mercator Gold System and Confirms High-Grade BIF Continuity
Mercator Gold Exploration Priorities & Strategy
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMP4 Therapeutics to Present New Preclinical Data Demonstrating CMP-002 Improves Seizure Threshold and Severity in a Model of SYNGAP1-Related Disorder